Herzuma

DRUG3 trials

Sponsors

Samsung Medical Center, National Cancer Center, Korea, Gangnam Severance Hospital

Conditions

HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 StudyHER2-positive Breast CancerMetastatic Breast CancerSalivary Duct Carcinoma

Phase 2

Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma

Samsung Medical CenterSalivary Duct Carcinoma

Start: 2018-09-20End: 2023-08-31Target: 41Updated: 2022-01-04

Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer

CompletedNCT03755141

National Cancer Center, KoreaHER2-positive Breast Cancer, Metastatic Breast Cancer

Start: 2018-12-15End: 2022-06-30Updated: 2025-07-22

Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)

RecruitingNCT04817540

Gangnam Severance HospitalHER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study

Start: 2021-09-01End: 2027-03-30Target: 59Updated: 2023-10-11

Related Papers

Abstract PO5-02-09: Discordance of the PAM50 intrinsic subtypes with the immunohistochemistry-based subtypes in HER2-negative early breast cancer treated with neoadjuvant chemotherapy

Cancer Research2024-05-02

Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08/KM11).

Journal of Clinical Oncology2022-06-016 citations